Results 1 to 10 of about 231 (96)

Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study [PDF]

Frontiers in Endocrinology, 2023
IntroductionThe standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing.
Roy Gomez, Mohamad Maghnie, Diane Turner-Bowker   +2 more
exaly   +4 more sources

Comparing the efficacy and safety of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
Summary Key takeaways Children living with growth hormone deficiency (GHD) are usually treated with daily injections of a growth hormone called somatropin to help them grow normally. Somatrogon is a growth hormone treatment that only needs to be injected
Roy Gomez, Vaman Khadilkar, Michael Wajnrajch   +2 more
exaly   +3 more sources

Understanding the burden of weekly somatrogon injections compared with daily somatropin injections in children with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• For children with growth hormone deficiency, once-weekly somatrogon injections were less of a burden than once-daily somatropin injections. • The safety of weekly somatrogon was similar to that of daily somatropin .
Sonya Galcheva
exaly   +3 more sources

Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• The efficacy of weekly somatrogon injections was no different from that of daily somatropin injections to treat children who don’t make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial. ○ Children
Cheri L. Deal, Joel Steelman, Elpis Vlachopapadopoulou, Renata Stawerska, Lawrence A. Silverman, Moshe Phillip, Ho-Seong Kim, CheolWoo Ko, Oleg Malievskiy, Jose F. Cara, Carl L. Roland, Carrie Turich Taylor, Srinivas Rao Valluri, Michael P. Wajnrajch, Aleksandra Pastrak, Bradley S. Miller   +15 more
exaly   +3 more sources

Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations [PDF]

Annals of Pediatric Endocrinology & Metabolism
Growth hormone (GH) is crucial for childhood growth and body composition. In pediatric GH deficiency (pGHD), the pituitary gland fails to produce sufficient GH, which affects linear growth in childhood.
Aristides K. Maniatis, Michael P. Wajnrajch, Marc Thomas, Sung Beom Chung, Jieun Lee   +4 more
doaj   +4 more sources

Two-year real-world experience with somatrogon in children and adolescents with growth hormone deficiency [PDF]

Frontiers in Endocrinology
IntroductionGrowth hormone deficiency (GHD) in children and adolescents is a chronic condition requiring long-term therapy with recombinant human growth hormone (rhGH).
Gianluca Tamaro, Gianluca Tamaro, Chiara Rodaro, Alice Fachin, Antonella Fabretto, Gianluca Tornese, Gianluca Tornese   +6 more
doaj   +6 more sources

Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogon. [PDF]

CPT Pharmacometrics Syst Pharmacol
AbstractFully Bayesian approaches are not commonly implemented for population pharmacokinetic (PK) modeling. In this paper, we evaluate the use of Stan with R and Torsten for population PK modeling of somatrogon, a recombinant long‐acting growth hormone approved for the treatment of growth hormone deficiency.
Wang Y, Pei X, Niu T, Korth-Bradley J, Fostvedt L.   +4 more
europepmc   +4 more sources

IGF-1 Assessment During Weekly Somatrogon Treatment in Pediatric Patients With GH Deficiency [PDF]

Journal of the Endocrine Society
Abstract Context In patients with GH deficiency (GHD) receiving GH treatment, IGF-1 concentrations are used by physicians to monitor treatment safety and efficacy and guide dosing decisions. Somatrogon is a long-acting GH approved as a once-weekly treatment for pediatric GHD. Somatrogon administration
Cheri Deal, Satyaprakash Nayak
exaly   +4 more sources

Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study [PDF]

Endocrine Journal
Somatrogon is a long-acting recombinant human growth hormone approved in several countries, including Japan, for the treatment of children with growth hormone deficiency (GHD).
Reiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, Tohru Yorifuji, David Ng, Ron G. Rosenfeld, Yuko Hoshino, Akifumi Okayama, Nozomi Ebata, Masayoshi Hosoi, Shinichi Nakamuta, Roy Gomez, Aleksandra Pastrak, Orlando Castellanos   +13 more
doaj   +2 more sources

Detection of the GH analogue somatrogon in doping control urine samples by means of LC-HRMS/MS [PDF]

Scientific Reports
Somatrogon is a synthetic growth hormone (GH) analog, whose misuse in sports is prohibited at all times. As analytical approaches complementary to existing immunological GH detection methods were considered beneficial for its detection in doping control ...
Katja Walpurgis, Andreas Thomas, Alexandra Rauer, Bettina Majer, Mitsuhiko Sato, Masato Okano, Maneera Al-Jaber, Wadha Abushareeda, Cristian-Gabriel Arsene, Hans Geyer, Mario Thevis   +10 more
doaj   +2 more sources